Eli Lilly and Company is trading 2.03% up at $30,200.00, following significant company-specific developments. - The company announced a strategic collaboration with BioArctic for neurodegeneration treatment development, including an initial payment of $30 million and potential milestones up to $770 million. - Eli Lilly's board also declared a third-quarter 2026 dividend of $1.73 per share. - Shares are rebounding from a recent pullback, having retreated from the $30,340.00 level last week.